儿童急性淋巴细胞白血病的预后评估

目前危险指向性治疗使儿童急性淋巴细胞白血病的治愈率接近80％。白血病细胞的分子基因分析和宿主的遗传药理研究是进一步改善预后的基础。评估微小残留病的早期治疗效应以综合反映白血病细胞的药物反应和宿主的遗传药理学，是调整治疗强度最可靠的指标。基因组和蛋白质组学技术有望鉴定个体化治疗的分子靶向。本文综述目前用于儿童ALL预后评估的危险因素及评估系统。

Prognosis Prediction for Childhood Acute Lymphoblastic Leukemia——Review

Contemporary risk-directed therapy has advanced the cure rate for childhood acute lymphoblastic leukemia to near 80%. Molecular genetic analyses of leukemic cells and pharmacogenetic studies of the host are providing a rational base for further improvement of treatment efficacy and the reduction of complications. Early treatment response, as defined by the measurement of minimal residual disease, reflects both the drug responsiveness of leukemic ceils and host pharmacogenomics, which is the most reliable prognostic indicator for gauging the intensity of treatment. High- throughput technologies in genomics and proteomics promise to identify risk classification and systems that incorporate well-established clinical parameters, genetic lesions of leukemic cells as well as early treatment response. The risk factors and systems of assessment in prognosis prediction for childhiod acude lymphoblasic leukemia were summarised in this review.